Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204603 | 0.88 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL14200213 | 0.86 | KDM4E (0.56) | KDM4ETSHRPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL10254237 | 0.85 | KDM4E (0.59) | KDM4ETSHRPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL10223621 | 0.84 | KDM4E (0.78) | KDM4ETSHRPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14200226 | 0.83 | KDM4E (0.60) | KDM4ETSHRPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL18376336 | 0.83 | POLB (0.63) | KDM4EEPHX2TSHRPOLBALDH1A1 | |
| SCHEMBL31539648 | 0.80 | ALDH1A1 (0.59) | KDM4EEPHX2TSHRPOLBALDH1A1 | |
| SCHEMBL20376289 | 0.80 | HTT (0.57) | KDM4EEPHX2TSHRPOLBALDH1A1 | |
| SCHEMBL21533988 | 0.79 | EPHX2 (0.39) | KDM4EEPHX2TSHRPOLBMAPK14 | |
| SCHEMBL12781675 | 0.79 | CYP2D6 (0.57) | KDM4ETSHRALDH1A1SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-08-24 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| WO-2021263205-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-11198677-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-12-14 | — | — | US | disclosed |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | SAI LIFE SCIENCES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | SAI LIFE SCIENCES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | KDM4E 1424/4885EPHX2 470/4885TSHR 4661/4885 |
| US-11584723-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | KDM4E 1424/4885EPHX2 470/4885TSHR 4661/4885 |
| US-20180194740-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE | DUT, DPYD, TYMP | KDM4E 1245/4885EPHX2 1138/4885TSHR 4292/4885 |
| US-20220402879-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | KDM4E 1424/4885EPHX2 470/4885TSHR 4661/4885 |
| US-20230263773-A1 | COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | TYMP, DUT, TYMS | KDM4E 1517/4885EPHX2 1609/4885TSHR 3469/4885 |
| US-11518746-B2 | Nitrogen ring linked deoxyuridine triphosphatase inhibitors | DUT, DPYD, TYMP | KDM4E 884/4885EPHX2 1141/4885TSHR 4475/4885 |
| US-11198677-B2 | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | DUT, DPYD, TYMP | KDM4E 1245/4885EPHX2 1138/4885TSHR 4292/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | KDM4E 1571/4885EPHX2 1483/4885TSHR 4749/4885 |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | KDM4E 1424/4885EPHX2 470/4885TSHR 4661/4885 |
| US-20190276410-A1 | NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, DPYD, TYMP | KDM4E 884/4885EPHX2 1141/4885TSHR 4475/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | KDM4E 1704/4885EPHX2 1930/4885TSHR 4777/4885 |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | DUT, DPYD, TYMP | KDM4E 1701/4885EPHX2 314/4885TSHR 4524/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | KDM4E 1424/4885EPHX2 470/4885TSHR 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.